Dublin, April 23, 2025 (GLOBE NEWSWIRE) -- The "GCC Pharmaceutical Market Opportunity & Clinical Trials Outlook 2030" has been added to ResearchAndMarkets.com's offering.
The Gulf Cooperation Council (GCC) pharmaceutical market is among the fastest-growing sectors globally, with Saudi Arabia spearheading regional growth. The market's expansion is fueled by an increasing population, longer life expectancy, and rising cases of lifestyle-related diseases. Saudi Arabia's pharmaceutical sector, valued at over US$ 5 billion, attracts major industry players like Pfizer and Novartis.
GCC Pharmaceutical Market Opportunity & Clinical Trials Outlook 2030 Report Highlights:
- GCC Pharmaceutical Market Opportunity: > US$ 12 Billion By 2030
- Saudi Arabia Domination GCC Pharmaceutical Market Landscape: > 50%
- Branded & Imported Drug Dominate GCC Pharmaceutical Market Landscape
- Number Of Drug Under Clinical Trials In GCC: > 250 Drugs
- Clinical Trials Insight By Company, Country, Indication & Phase
- Regulatory, Reimbursement and Insurance Insight By Country
- Local & International Pharmaceutical Companies Insight
- GCC Drug Registration Process
Healthcare initiatives, such as the UAE's Dubai Health Strategy and Saudi Arabia's Vision 2030, are driving significant growth. Investments in healthcare infrastructure, including the establishment of healthcare cities like King Abdullah Medical City and Dubai Healthcare City, are turning these regions into pharmaceutical and medical excellence hubs. Mandatory health insurance schemes have improved prescription medication access, further boosting pharmaceutical sales.
Although imported pharmaceuticals currently dominate the market, local manufacturing is on the rise. Companies like Saudi Arabia's SPIMACO and UAE's Julphar are notable local manufacturers, initially focusing on generics and expanding into more complex products like biosimilars.
Lifestyle-related diseases significantly impact demand, with the GCC exhibiting some of the world's highest diabetes rates. Countries like Saudi Arabia and Kuwait report diabetes prevalence rates of over 15%, creating substantial markets for diabetes and cardiovascular drugs.
Digital health integration is transforming distribution and service efficiency. Initiatives like UAE's Smart Dubai and Kuwait's e-prescription services have improved pharmaceutical distribution and reduced medication errors, providing opportunities for companies to strengthen market presence.
The generics market is experiencing rapid growth as governments strive to cut healthcare costs. Saudi Arabia's generic substitution policy has increased generic drug utilization significantly, a trend mirrored across the GCC. Local manufacturers such as Jamjoom Pharma are thriving by producing high-quality generic alternatives.
While facing challenges like price control measures, the market's demand for specialized medications presents ample opportunities. The oncology drugs segment is expanding, fueled by higher cancer incidence and improved diagnostics. The biosimilars market is also poised for growth, with investments in biological drug production facilities in Saudi Arabia and the UAE.
The regulatory environment is evolving, with entities like the Gulf Central Committee for Drug Registration enhancing market access while ensuring quality standards. Streamlined pathways for innovative medications, such as Saudi Arabia's accelerated registration and the UAE's fast-track system, underscore robust market fundamentals and government support. These factors suggest continued growth of the GCC pharmaceutical market towards greater sophistication and self-reliance.
Company Coverage Includes:
- Julphur Pharmaceuticals
- SPIMACO Addwaeih
- Qatar Life Pharma
- Al Mojil Drug Company
- Kuwait Saudi Pharmaceutical Company
- YIACO Medical Company
- Qatar Pharma
- Saja Pharmaceuticals
- Oman Pharmaceuticals
- Taiba Pharmaceuticals
- Gulf Biotech
- Bahrain Pharma
- Neopharma
- Planet Pharmacies
- Aljazeera Pharmaceutical Industries
- Dallah Pharma
- Tabuk Pharmaceuticals
- ACDIMA
- AL-Mufid Pharmaceuticals
- Novartis
- Amgen
- Eli - Lilly
- Merck
- Pfizer
- GlaxoSmithKline
- Roche
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- AstraZeneca
- Genentech
- Sanofi
Key Topics Covered:
1. GCC Pharmaceutical Market Landscape
1.1 Current Scenario
1.2 GCC Clinical Trials Landscape
1.3 GCC Drug Registration Process
2. GCC Pharmaceutical Market Dynamics & Outlook
2.1 Current Market Overview
2.2 Future Market Opportunities
3. Saudi Arabia Pharmaceutical Market Analysis
3.1 Overview
3.2 Regulatory Framework
3.3 Branded v/s Generic Drugs Availability
3.4 Reimbursement and Insurance Insight
4. Saudi Arabia Clinical Trials Insight By Company, Indication & Phase
5. Saudi Arabia Marketed Drugs Clinical Insight By Company & Indication
6. UAE Pharmaceutical Market Analysis
6.1 Overview
6.2 Regulatory Framework
6.3 Branded v/s Generic Drugs Availability
6.4 Reimbursement and Insurance Insight
7. United Arab Emirates Clinical Trials Insight By Company, Indication & Phase
8. Qatar Pharmaceutical Market Analysis
8.1 Overview
8.2 Regulatory Framework
8.3 Branded v/s Generic Drugs Availability
8.4 Reimbursement and Insurance Insight
9. Qatar Clinical Trials Insight By Company, Indication & Phase
10. Qatar Marketed Drugs Clinical insight By Company & Indication
11. Oman Pharmaceutical Market Analysis
11.1 Overview
11.2 Regulatory Framework
11.3 Branded v/s Generic Drugs Availability
11.4 Reimbursement & Insurance Insight
12. Oman Clinical Trials Insight By Company, Indication & Phase
13. Oman Marketed Drugs Clinical insight By Company & Indication
14. Kuwait Pharmaceutical Market Analysis
14.1 Overview
14.2 Regulatory Framework
14.3 Branded v/s Generic Drugs Availability
14.4 Reimbursement and Insurance Insight
15. Kuwait Clinical Trials Insight By Company, Indication & Phase
16. Kuwait Marketed Drugs Clinical insight By Company & Indication
17. Bahrain Pharmaceutical Market Analysis
17.1 Overview
17.2 Regulatory Framework
17.3 Branded v/s Generic Drugs Availability
17.4 Reimbursement and Insurance Insight
18. Bahrain Clinical Trials Insight By Company, Indication & Phase
19. Bahrain Marketed Drugs Clinical insight By Company & Indication
20. GCC Pharmaceutical Market Drivers & Challenges
20.1 Drivers & Opportunities
20.2 Challenges & Restraints
21. Competitive Landscape
21.1 Local Pharmaceutical Companies
21.2 Multinational Companies
For more information about this report visit http://www.researchandmarkets.com/r/j05deq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
